Letermovir compared with valganciclovir to prevent CMV infection after kidney transplant
Tests letermovir against valganciclovir for preventing CMV in kidney transplant recipients.
Key facts
- Who runs it
- Elisabeth Kincaide
- Where
- San Antonio, United StatesSee the site
- Trial code
- Registry title
- Letermovir vs Valganciclovir in CMV R+ Kidney Transplant
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 300 people, planned
- Started
- May 2026
- Expected to end
- Nov 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Letermovir
- Valganciclovir CMV Prophylaxis
- Record updated
- 8 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who received a kidney transplant and already carry CMV antibodies. It compares letermovir with past patients given valganciclovir for 90 days to prevent CMV infection.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Kidney transplant recipients who are CMV positive (R+), shown by a CMV IgG test within 90 days before the transplant.
- Earlier treatment
- No anti-CMV drug within 7 days before joining. No earlier solid organ transplant or stem cell transplant (HSCT). Letermovir group: no earlier letermovir study or other CMV test-drug study.
- Biomarker or test result
- Positive CMV IgG blood test (R+) within 90 days before transplant.
Main reasons for not taking part
- Transplant of more than one organ, or an earlier transplant.
- Past CMV disease, or uncontrolled infection at enrolment.
- Hepatitis B (HBsAg) or detectable hepatitis C (HCV RNA), or a donor with HCV.
- Pregnant, breastfeeding, or planning pregnancy during the study.
- Letermovir group: on dialysis or plasmapheresis, or severe liver failure (Child-Pugh Class C).
This trial only enrols participants who have had an organ transplant. The registry sentence this rests on: * Kidney transplant recipient with documented CMV IgG seropositive status (R+) within 90 days prior to transplant
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- ≥18 years old
- Kidney transplant recipient with documented CMV IgG seropositive status (R+) within 90 days prior to transplant
- Males agree to use contraception and refraining from donating sperm for 290 days post-treatment initiation
- Females of child-bearing potential agree to follow contraception guidance for 290 days post-treatment initiation
Who cannot take part
- Multiorgan organ transplant
- Received previous solid organ transplant or HSCT
- Unable to take oral medications
- Documented HBsAg or detectable HCV RNA 90 days prior to enrollment or HCV+ donor
- Received any anti-CMV drug treatment within 7 days prior to enrollment
- Current user of recreational or illicit drugs or alcohol dependence
- History of CMV disease prior to enrollment
- Previously participated in a letermovir study or any other study with CMV investigational agents
- Uncontrolled infections at the time of enrollment
- Known or suspected hypersensitivity to active or inactive ingredients from letermovir or acyclovir formulations
- Child-Pugh Class C severe hepatic insufficiency
- Hemodynamically unstable or on mechanical ventilation at the time of enrollment
- Pregnant or breastfeeding or planning to be pregnant, breastfeeding or donating eggs during study period and 90 days post cessation
- On dialysis or plasmapheresis at the time of enrollment
- Currently participating or has participated in a study with an unapproved compound of device within 28 days or 5 half-lives of this study
- Contraindications per letermovir or acyclovir package insert: patients on pimozide, ergot alkaloids; or pitavastatin and simvastatin when co-administered with cyclosporine
Where in United States
- University HospitalSan Antonio, United StatesContact: Elisabeth Kincaide, PharmDNot yet recruiting
About the trial
What the trial wants to find out
The purpose of this study is to find out whether letermovir can help prevent cytomegalovirus (CMV) infection in kidney transplant recipients who are CMV seropositive. To do this, researchers will compare patients who received letermovir with a group of historical patients who received valganciclovir ("mini dose"). Both groups will be on CMV prophylaxis drug for 90 days post-transplant.
Read full original descriptionShow less
The main question the study wants to answer is:
• Does letermovir work as well as valganciclovir in preventing CMV infections during the first 12 months after a kidney transplant?
The study will also look at other important questions:
* Is letermovir easier for patients to tolerate than valganciclovir? * How long does it take for a CMV infection to appear in each group? * Are there differences in "breakthrough" CMV infections between the two medications? * For patients who develop CMV that becomes resistant to treatment, are the resistance patterns different between the two groups
The 2 groups in the trial
- LetermovirExisting treatment, for comparison
Prospective letermovir prophylaxis
- ValganciclovirOther group
Historical valganciclovir prophylaxis
Treatment: Valganciclovir CMV Prophylaxis
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Letermovir Versus Valganciclovir for 90 Days in CMV Seropositive Kidney Transplant Recipients: Results of a Single-center Experience.
- Plain-language title
- Letermovir compared with valganciclovir to prevent CMV infection after kidney transplantGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 8 May 2026